scispace - formally typeset
R

Robert Fagard

Researcher at Katholieke Universiteit Leuven

Publications -  788
Citations -  109235

Robert Fagard is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 114, co-authored 787 publications receiving 104613 citations.

Papers
More filters
Journal ArticleDOI

TGF-β1-induced cardiac myofibroblasts are nonproliferating functional cells carrying DNA damages

TL;DR: It is suggested that TGF-beta1-activated MyoFbs can be growth-arrested by two checkpoints, the G1/S checkpoint, which prevents cells from entering S-phase and the intra-S checkpoints, which is activated by encountering DNA damage during the S phase or by unrepaired damage that escapes the G 1/S checkpoints.
Journal ArticleDOI

Left ventricular hypertrophy is a predictor of cardiovascular events in elderly hypertensive patients: Hypertension in the Very Elderly Trial.

TL;DR: Use of Cornell voltage and Cornell product criteria for LVH predicted the risk of cardiovascular disease and stroke and the identification of ECG LVH proved to be important in very elderly hypertensive people.
Journal ArticleDOI

The Trough-to-Peak Ratio as an Instrument to Evaluate Antihypertensive Drugs

TL;DR: In 66 patients examined twice on 10 mg lisinopril at a median interval of 32 days, the trough-to-peak ratios were characterized by large intraindividual variability, and by smoothing of the diurnal blood pressure profiles.
Journal ArticleDOI

Heritability of left ventricular structure and function in Caucasian families

TL;DR: The study demonstrated moderate heritability for LV mass as well as the mitral annular Ea and Aa peaks, which support the ongoing research to map and detect genetic variants that contribute to the variation in LV mass and other LV structural and functional phenotypes.
Journal ArticleDOI

Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments.

TL;DR: The result suggests that the apparent effect on blood pressure is not the only cause of stroke risk reduction in hypertensive subjects submitted to an antihypertensive medicine, and that the mechanism of risk reduction obtained by blood pressure‐lowering pharmacological treatment remains unclear.